The ITA.LI.CA Staging System: A Novel Staging System for Hepatocellular Carcinoma

English version České info

In this Perspective, Neehar Parikh and Amit Singal discuss the advantages of the ITA.LI.CA staging system for prognoses of liver cancer developed by Alessandro Vitale and colleagues.

Vyšlo v časopise: The ITA.LI.CA Staging System: A Novel Staging System for Hepatocellular Carcinoma. PLoS Med 13(4): e32767. doi:10.1371/journal.pmed.1002005
Kategorie: Perspective
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1002005

Souhrn

In this Perspective, Neehar Parikh and Amit Singal discuss the advantages of the ITA.LI.CA staging system for prognoses of liver cancer developed by Alessandro Vitale and colleagues.

Zdroje

1. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19(3):329–38. Epub 1999/10/13. doi: 10.1055/s-2007-1007122 10518312.

2. Yau T, Tang VY, Yao TJ, Fan ST, Lo CM, Poon RT. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology. 2014;146(7):1691–700.e3. doi: 10.1053/j.gastro.2014.02.032 24583061.

3. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology. 1998;28(3):751–5. doi: 10.1002/hep.510280322 9731568.

4. Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol. 2003;38(3):207–15. doi: 10.1007/s005350300038 12673442.

5. Yang JD, Kim WR, Park KW, Chaiteerakij R, Kim B, Sanderson SO, et al. Model to estimate survival in ambulatory patients with hepatocellular carcinoma. Hepatology. 2012;56(2):614–21. doi: 10.1002/hep.25680 22370914; PubMed Central PMCID: PMC3564594.

6. Farinati F, Vitale A, Spolverato G, Pawlik TM, Huo T-l, Lee Y-H, et al. Development and validation of a new prognostic system for patients with hepatocellular carcinoma. PLoS Med. 2016;13(4): e1002006.

7. European Association For The Study Of The L, European Organisation For R, Treatment Of C. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–43. doi: 10.1016/j.jhep.2011.12.001 22424438.

8. Bruix J, Sherman M, American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–2. doi: 10.1002/hep.24199 21374666; PubMed Central PMCID: PMC3084991.

9. Bolondi L, Burroughs A, Dufour JF, Galle PR, Mazzaferro V, Piscaglia F, et al. Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis. 2012;32(4):348–59. doi: 10.1055/s-0032-1329906 23397536.

10. Arizumi T, Ueshima K, Iwanishi M, Minami T, Chishina H, Kono M, et al. Validation of a Modified Substaging System (Kinki Criteria) for Patients with Intermediate-Stage Hepatocellular Carcinoma. Oncology. 2015;89 Suppl 2:47–52. doi: 10.1159/000440631 26584036.

11. Yoo JJ, Lee JH, Lee SH, Lee M, Lee DH, Cho Y, et al. Comparison of the effects of transarterial chemoembolization for advanced hepatocellular carcinoma between patients with and without extrahepatic metastases. PLoS ONE. 2014;9(11):e113926. doi: 10.1371/journal.pone.0113926 25427152; PubMed Central PMCID: PMC4245068.

12. Mehta N, Sarkar M, Dodge JL, Fidelman N, Roberts JP, Yao FY. Intention to treat outcome of T1 hepatocellular carcinoma with the "wait and not ablate" approach until meeting T2 criteria for liver transplant listing. Liver Transpl. 2016;22(2):178–87. doi: 10.1002/lt.24360 26479422.